Table 3 Biomarkers for checkpoint inhibitors: prognostic (in italics) and predictive details
From: Future perspectives in melanoma research “Melanoma Bridge”, Napoli, November 30th–3rd December 2016
Ipilimumab | Pembrolizumab |
|---|---|
Lactate dehydrogenase | Stage III-IVB/IVC |
Relative lymphocyte counts (RLC) | Lactate dehydrogenase (LDH) |
Absolute eosinophil counts (AEC) | Relative lymphocyte counts (RLC) |
Absolute monocyte counts (AMC) | Relative eosinophil counts (REC) |
Tregs: unknown | |
MDSC: unknown | |
γδ T-cells: uncertain | |
Increase CD4+ CD8+ T cell: uncertain |